Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion type Assertion NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_head.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion wasGeneratedBy ECO_0000203 NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_provenance.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion wasDerivedFrom befree-2016 NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_provenance.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion SIO_000772 23931927 NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_provenance.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion evidence source_evidence_literature NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_provenance.
- NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_assertion description "[Crizotinib, a first-in-class dual ALK and c-MET inhibitor, has been shown to be particularly effective against ALK positive NSCLC, showing dramatic and prolonged responses with low toxicity, predominantly restricted to the gastro-intestinal and visual systems, and generally self-limiting or easily managed.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1100904.RAXruq6TI9C37tE9dA2fSPWyrddGJjqD1bIuHzF7Kyabg130_provenance.